About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Back in the Stacks | Main | Per Fits and Starts, Ad Astra »

January 12, 2003

Easy Parts and Hard Parts

Email This Entry

Posted by Derek

I've been reading George Dyson's interesting history of Project Orion, the late-1950s attempt to design a spacecraft powered by sequential nuclear explosions. (A borderline crazy idea, it very likely would have worked. The big question became whether it should be allowed to work at all.)

He quotes his father, Freeman Dyson, about the early days of the project:

"Everybody did a little of everything. There was no division of the staff into phgysicists and engineers. The ethos of engineering is very different from that of physics. A good physicist is a man with original ideas. A good engineer is a man who makes a design that works with as few original ideas as possible."

There's a lot of truth to that. So in which category is work in medicinal chemistry? The answer isn't immediately obvious, especially for people just starting out in the business. In graduate school, the emphasis is (rightly) on the pure science: as many original ideas as possible (as long as you can get them to work, one way or another.) So when freshly coined PhDs or post-docs join a drug company, they're sometimes under the illusion that unusual new chemistry is what's called for at every opportunity.

And nothing could be further from the truth. From an organic chemistry standpoint, medicinal chemistry can be downright boring. The sooner that new researchers figure that out, the better off they are. You can do perfectly respectable medicinal chemistry using nothing but reactions and ideas from an undergraduate textbook. (As I've pointed out, those reactions got to be classics because they tend to work, which is just what you need.)

The point of medicinal chemistry isn't chemistry; that's just the means to the end. We do just as much cutting-edge chemistry as we have to, and no more. That stuff takes a lot of time to figure out - and we have plenty of other problems that are waiting to take plenty of our time. The chemistry had better just quietly work for the most part, if you're going to have a chance.

The original ideas come when it's time to decide what molecules to make, and when it's time to figure out why you're getting the biological effects from them that you are. In those areas, we'll take all the original thinking that anyone can provide. Any weird brainstorms about how to make a compound more potent or more selective are welcome. And if making those new molecules calls for nothing more than ancient reactions, yawners that bore the pants off everyone who does them, then so much the better: that means that the molecules will be made quickly and in a good quantity. (One of the worst binds you can be caught in is to have a wonderful lead structure that you can't find a way to make enough of.)

So, when it comes to chemistry, we're engineers. When it comes to medicines, though, we'd better be the next best thing to poets.

Comments (0) + TrackBacks (0) | Category: Who Discovers and Why



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry